Evaluation and treatment of erectile dysfunction

Medical Clinics of North America

Volumn 95, Issue 1, 2011, Pages 201-212

  Albersen, Maarten ^a   Mwamukonda, Kuwong B ^b   Shindel, Alan W ^c   Lue, Tom F ^d  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b BROOKE ARMY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apomorphine SL; Assessment; Erectile dysfunction; Evaluation; Intracavernous injection; Phosphodiesterase 5 inhibitors; Prostaglandin; Treatment

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIANDROGEN; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; APOMORPHINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ERYTHROMYCIN; KETOCONAZOLE; NEUROLEPTIC AGENT; NITRATE; PAPAVERINE; PHENOBARBITAL; PHENTOLAMINE; PHENYTOIN; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1; PROTEINASE INHIBITOR; RIFAMPICIN; SILDENAFIL; TADALAFIL; TESTOSTERONE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VARDENAFIL; VASOACTIVE INTESTINAL POLYPEPTIDE; YOHIMBINE;

ADULT; AGED; AGING; ALGORITHM; ANTIHYPERTENSIVE THERAPY; BACKACHE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL PRACTICE; COMORBIDITY; DEVICE; DIABETES MELLITUS; DIAGNOSTIC TEST; DIZZINESS; DOPPLER ECHOGRAPHY; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ERECTILE DYSFUNCTION; FACE PAIN; FLUSHING; HEADACHE; HEARING LOSS; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPEREMIA; HYPERTENSION; HYPOGONADISM; HYPOTENSION; IATROGENIC DISEASE; IMPLANTATION; INFECTION; LABORATORY TEST; MALE; MALE SEXUAL DYSFUNCTION; MEDICAL SPECIALIST; MEDICATED URETHRAL SYSTEM FOR ERECTION; METABOLIC SYNDROME X; MYALGIA; NAUSEA; NOSE CONGESTION; OPTIC NEURITIS; PAIN; PATHOPHYSIOLOGY; PATIENT EDUCATION; PATIENT REFERRAL; PENILE FIBROSIS; PENIS; PENIS ERECTION; PENIS PROSTHESIS; PHYSICAL EXAMINATION; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PREVALENCE; PRIAPISM; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QT PROLONGATION; QUESTIONNAIRE; RECOMMENDED DRUG DOSE; REVASCULARIZATION; REVIEW; RISK ASSESSMENT; SEIZURE; SEXUAL BEHAVIOR; SEXUAL SATISFACTION; SIDE EFFECT; SYNCOPE; TREATMENT FAILURE; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS; URETHRAL PAIN; VACUUM CONSTRICTION DEVICE; VEIN LIGATION; VISUAL DISORDER;

APOMORPHINE; EQUIPMENT AND SUPPLIES; ERECTILE DYSFUNCTION; HUMANS; MALE; PHOSPHODIESTERASE 5 INHIBITORS; PRIMARY HEALTH CARE; REFERRAL AND CONSULTATION; UROGENITAL SURGICAL PROCEDURES;

EID: 78649392065     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2010.08.016     Document Type: Review

References (32)

1. NIH Consensus Conference Impotence. NIH consensus development panel on impotence. JAMA 1993, 270(1):83-90.
2. Uckert S., Mayer M.E., Stief C.G., et al. The future of the oral pharmacotherapy of male erectile dysfunction: things to come. Expert Opin Emerg Drugs 2007, 12(2):219-228.
3. Saigal C.S., Wessells H., Pace J., et al. Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med 2006, 166(2):207-212.
4. Lue T.F. Erectile dysfunction. N Engl J Med 2000, 342(24):1802-1813.
5. Araujo A.B., Travison T.G., Ganz P., et al. Erectile dysfunction and mortality. J Sex Med 2009, 6(9):2445-2454.
6. Guo W, Liao C, Zou Y, et al. Erectile dysfunction and risk of clinical cardiovascular events: a meta-analysis of seven cohort studies. J Sex Med 2010. [Epub ahead of print].
7. Albersen M., Shindel A.W., Mwamukonda K.B., et al. The future is today: emerging drugs for the treatment of erectile dysfunction. Expert Opin Emerg Drugs 2010, 15(3):467-480.
8. Gratzke C., Angulo J., Chitaley K., et al. Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med 2010, 7(1 Pt 2):445-475.
9. Lin C.S., Xin Z.C., Wang Z., et al. Molecular Yin and Yang of erectile function and dysfunction. Asian J Androl 2008, 10(3):433-440.
10. Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010. [Epub ahead of print].
11. Albersen M., Shindel A.W., Lue T.F. Sexual dysfunction in the older man. Rev Clin Gerontol 2009, 19:b1-b8.
12. Kostis J.B., Jackson G., Rosen R., et al. Sexual dysfunction and cardiac risk (the second Princeton Consensus Conference). Am J Cardiol 2005, 96(2):313-321.
13. Hackett G., Kell P., Ralph D., et al. British Society for Sexual Medicine guidelines on the management of erectile dysfunction. J Sex Med 2008, 5(8):1841-1865.
14. Kloner R.A. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. Am J Cardiol 2005, 96(12B):42M-46M.
15. Rosen R.C., Cappelleri J.C., Gendrano N. The international index of erectile function (IIEF): a state-of-the-science review. Int J Impot Res 2002, 14(4):226-244.
16. Rosen R.C., Cappelleri J.C., Smith M.D., et al. Development and evaluation of an abridged, 5-item version of the International index of erectile function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999, 11(6):319-326.
17. Greene K.L., Albertsen P.C., Babaian R.J., et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2009, 182(5):2232-2241.
18. Esposito K., Giugliano F., Di Palo C., et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004, 291(24):2978-2984.
19. Eardley I., Donatucci C., Corbin J., et al. Pharmacotherapy for erectile dysfunction. J Sex Med 2010, 7(1 Pt 2):524-540.
20. Hatzimouratidis K., Hatzichristou D.G. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?. Drugs 2005, 65(12):1621-1650.
21. Shindel A.W. 2009 update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class. J Sex Med 2009, 6(9):2352-2364.
22. Carson C.C. Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors. Am J Cardiol 2005, 96(12B):37M-41M.
23. Jannini E.A., Isidori A.M., Gravina G.L., et al. The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction. J Sex Med 2009, 6(9):2547-2560.
24. Hatzimouratidis K., Hatzichristou D. Phosphodiesterase type 5 inhibitors: the day after. Eur Urol 2007, 51(1):75-88.
25. Bella A.J., Brant W.O., Lue T.F., et al. Non-arteritic anterior ischemic optic neuropathy (NAION) and phosphodiesterase type-5 inhibitors. Can J Urol 2006, 13(5):3233-3238.
26. Bella A.J., Deyoung L.X., Al-Numi M., et al. Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Eur Urol 2007, 52(4):990-1005.
27. Shindel A.W. 2009 update on phosphodiesterase type 5 inhibitor therapy part 1: recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME). J Sex Med 2009, 6(7):1794-1808. [quiz: 1793, 1809-10].
28. Rubio-Aurioles E., Kim E.D., Rosen R.C., et al. Impact on erectile function and sexual quality of life of couples: a double-blind, randomized, placebo-controlled trial of tadalafil taken once daily. J Sex Med 2009, 6(5):1314-1323.
29. Shabsigh R., Kaufman J.M., Steidle C., et al. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004, 172(2):658-663.
30. Heaton J.P., Altwein J.E. The role of apomorphine SL in the treatment of male erectile dysfunction. BJU Int 2001, 88(Suppl 3):36-38.
31. Costabile R.A., Mammen T., Hwang K. An overview and expert opinion on the use of alprostadil in the treatment of sexual dysfunction. Expert Opin Pharmacother 2008, 9(8):1421-1429.
32. Alexandre B., Lemaire A., Desvaux P., et al. Intracavernous injections of prostaglandin E1 for erectile dysfunction: patient satisfaction and quality of sex life on long-term treatment. J Sex Med 2007, 4(2):426-431.